Description
This session will review the rationale behind anti-PD-1 checkpoint inhibitor therapy in cervical and vulvar carcinomas and describe how PD-L1 immunohistochemical staining is used as a predictive biomarker in these tumors. Alternate approved biomarkers for anti-PD-1 therapy across all solid tumors, such as mismatch repair deficiency and tumor mutational burden, will also be briefly discussed. The session will conclude with a discussion of possible reasons for limited response to immunotherapy in these tumors and an introduction to emerging biomarkers that may improve patient selection in the future.
Objectives
1. Cite trials leading to anti-PD-1 approval in cervical carcinoma.
2. Score PD-L1 immunohistochemistry in cervical carcinoma.